Antitumor effect of dobutamine on multiple myeloma via mitogen-activated protein kinase pathway in vitro
Multiple myeloma （MM） is one of the most malignant cancers and is characterized by infiltration of bone marrow by plasma cells, secretion of monoclonal immunoglobulins and osteolytic lesions, and its incidence is increasing in the middle-aged and elderly patients . As MM cells are heterogeneous and...
Gespeichert in:
| Veröffentlicht in: | Acta biochimica et biophysica Sinica 2016-12, Vol.48 (12), p.1135-1137 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1137 |
|---|---|
| container_issue | 12 |
| container_start_page | 1135 |
| container_title | Acta biochimica et biophysica Sinica |
| container_volume | 48 |
| creator | Xie, Bingqian Xu, Zhijian Yang, Guang Chen, Gege Li, Bo Hu, Liangning Xiao, Wenqin Sun, Xi Gao, Minjie Gao, Lu Wu, Xiaosong Tao, Yi Zhu, Weiliang Shi, Jumei |
| description | Multiple myeloma （MM） is one of the most malignant cancers and is characterized by infiltration of bone marrow by plasma cells, secretion of monoclonal immunoglobulins and osteolytic lesions, and its incidence is increasing in the middle-aged and elderly patients . As MM cells are heterogeneous and drug resistant, ini- tial MM usually progresses to the relapsed/refractory stage. Although existing therapies such as thalidomide, bortezomib, and lenalidomide can prolong the survival of MM patients, MM is still regarded as incurable. Therefore, it is necessary to establish new effective therapies to treat relapsed/refractory MM. |
| doi_str_mv | 10.1093/abbs/gmw110 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1834997706</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>671151492</cqvip_id><sourcerecordid>1834997706</sourcerecordid><originalsourceid>FETCH-LOGICAL-c316t-c4798303d1445b3bb810131f0cddd668e1d6029e242e890ff9bc55c070dc72013</originalsourceid><addsrcrecordid>eNo9kEFP3DAQRq0KVCj01DuyOCFVAY-d2PERIWgrIfVSzpFjT3YNsb3EzqL99w3ahdN8Gj19mnmE_AB2DUyLG9P3-WYV3gDYF3IKqm4qxRU7WrJUvNJQNyfkW87PjAkpgX0lJ1wprRTnp2R9G4svc0gTxWFAW2gaqEv9XEzwEWmKNMxj8ZsRadjhmIKhW29o8CWtMFbGFr81BR3dTKmgj_TFR5ORbkxZv5kdXTZbX6Z0To4HM2b8fphn5Onh_t_d7-rx768_d7ePlRUgS2VrpVvBhIO6bnrR9y0wEDAw65yTskVwknGNvObYajYMurdNY5liziq-oGfkat-73PM6Yy5d8NniOJqIac4dtKLWy_NMLujPPWqnlPOEQ7eZfDDTrgPWvavt3tV2e7ULfXEonvuA7pP9cLkAl4e6dYqrVx9Xn4xUAA3Umov_4hWCcA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1834997706</pqid></control><display><type>article</type><title>Antitumor effect of dobutamine on multiple myeloma via mitogen-activated protein kinase pathway in vitro</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Xie, Bingqian ; Xu, Zhijian ; Yang, Guang ; Chen, Gege ; Li, Bo ; Hu, Liangning ; Xiao, Wenqin ; Sun, Xi ; Gao, Minjie ; Gao, Lu ; Wu, Xiaosong ; Tao, Yi ; Zhu, Weiliang ; Shi, Jumei</creator><creatorcontrib>Xie, Bingqian ; Xu, Zhijian ; Yang, Guang ; Chen, Gege ; Li, Bo ; Hu, Liangning ; Xiao, Wenqin ; Sun, Xi ; Gao, Minjie ; Gao, Lu ; Wu, Xiaosong ; Tao, Yi ; Zhu, Weiliang ; Shi, Jumei</creatorcontrib><description>Multiple myeloma （MM） is one of the most malignant cancers and is characterized by infiltration of bone marrow by plasma cells, secretion of monoclonal immunoglobulins and osteolytic lesions, and its incidence is increasing in the middle-aged and elderly patients . As MM cells are heterogeneous and drug resistant, ini- tial MM usually progresses to the relapsed/refractory stage. Although existing therapies such as thalidomide, bortezomib, and lenalidomide can prolong the survival of MM patients, MM is still regarded as incurable. Therefore, it is necessary to establish new effective therapies to treat relapsed/refractory MM.</description><identifier>ISSN: 1672-9145</identifier><identifier>EISSN: 1745-7270</identifier><identifier>DOI: 10.1093/abbs/gmw110</identifier><identifier>PMID: 27797722</identifier><language>eng</language><publisher>China</publisher><subject>Antineoplastic Agents - therapeutic use ; Cell Line, Tumor ; Dobutamine - therapeutic use ; Humans ; In Vitro Techniques ; Mitogen-Activated Protein Kinases - drug effects ; Multiple Myeloma - drug therapy ; Multiple Myeloma - pathology ; 丝裂原活化蛋白激酶 ; 体外 ; 信号通路 ; 免疫球蛋白 ; 多发性骨髓瘤 ; 患者 ; 抗肿瘤作用 ; 沙利度胺</subject><ispartof>Acta biochimica et biophysica Sinica, 2016-12, Vol.48 (12), p.1135-1137</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c316t-c4798303d1445b3bb810131f0cddd668e1d6029e242e890ff9bc55c070dc72013</citedby><cites>FETCH-LOGICAL-c316t-c4798303d1445b3bb810131f0cddd668e1d6029e242e890ff9bc55c070dc72013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/90160X/90160X.jpg</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27797722$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xie, Bingqian</creatorcontrib><creatorcontrib>Xu, Zhijian</creatorcontrib><creatorcontrib>Yang, Guang</creatorcontrib><creatorcontrib>Chen, Gege</creatorcontrib><creatorcontrib>Li, Bo</creatorcontrib><creatorcontrib>Hu, Liangning</creatorcontrib><creatorcontrib>Xiao, Wenqin</creatorcontrib><creatorcontrib>Sun, Xi</creatorcontrib><creatorcontrib>Gao, Minjie</creatorcontrib><creatorcontrib>Gao, Lu</creatorcontrib><creatorcontrib>Wu, Xiaosong</creatorcontrib><creatorcontrib>Tao, Yi</creatorcontrib><creatorcontrib>Zhu, Weiliang</creatorcontrib><creatorcontrib>Shi, Jumei</creatorcontrib><title>Antitumor effect of dobutamine on multiple myeloma via mitogen-activated protein kinase pathway in vitro</title><title>Acta biochimica et biophysica Sinica</title><addtitle>Acta Biochimica et Biophysica Sinica</addtitle><description>Multiple myeloma （MM） is one of the most malignant cancers and is characterized by infiltration of bone marrow by plasma cells, secretion of monoclonal immunoglobulins and osteolytic lesions, and its incidence is increasing in the middle-aged and elderly patients . As MM cells are heterogeneous and drug resistant, ini- tial MM usually progresses to the relapsed/refractory stage. Although existing therapies such as thalidomide, bortezomib, and lenalidomide can prolong the survival of MM patients, MM is still regarded as incurable. Therefore, it is necessary to establish new effective therapies to treat relapsed/refractory MM.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cell Line, Tumor</subject><subject>Dobutamine - therapeutic use</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Mitogen-Activated Protein Kinases - drug effects</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - pathology</subject><subject>丝裂原活化蛋白激酶</subject><subject>体外</subject><subject>信号通路</subject><subject>免疫球蛋白</subject><subject>多发性骨髓瘤</subject><subject>患者</subject><subject>抗肿瘤作用</subject><subject>沙利度胺</subject><issn>1672-9145</issn><issn>1745-7270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEFP3DAQRq0KVCj01DuyOCFVAY-d2PERIWgrIfVSzpFjT3YNsb3EzqL99w3ahdN8Gj19mnmE_AB2DUyLG9P3-WYV3gDYF3IKqm4qxRU7WrJUvNJQNyfkW87PjAkpgX0lJ1wprRTnp2R9G4svc0gTxWFAW2gaqEv9XEzwEWmKNMxj8ZsRadjhmIKhW29o8CWtMFbGFr81BR3dTKmgj_TFR5ORbkxZv5kdXTZbX6Z0To4HM2b8fphn5Onh_t_d7-rx768_d7ePlRUgS2VrpVvBhIO6bnrR9y0wEDAw65yTskVwknGNvObYajYMurdNY5liziq-oGfkat-73PM6Yy5d8NniOJqIac4dtKLWy_NMLujPPWqnlPOEQ7eZfDDTrgPWvavt3tV2e7ULfXEonvuA7pP9cLkAl4e6dYqrVx9Xn4xUAA3Umov_4hWCcA</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Xie, Bingqian</creator><creator>Xu, Zhijian</creator><creator>Yang, Guang</creator><creator>Chen, Gege</creator><creator>Li, Bo</creator><creator>Hu, Liangning</creator><creator>Xiao, Wenqin</creator><creator>Sun, Xi</creator><creator>Gao, Minjie</creator><creator>Gao, Lu</creator><creator>Wu, Xiaosong</creator><creator>Tao, Yi</creator><creator>Zhu, Weiliang</creator><creator>Shi, Jumei</creator><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W94</scope><scope>WU4</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20161201</creationdate><title>Antitumor effect of dobutamine on multiple myeloma via mitogen-activated protein kinase pathway in vitro</title><author>Xie, Bingqian ; Xu, Zhijian ; Yang, Guang ; Chen, Gege ; Li, Bo ; Hu, Liangning ; Xiao, Wenqin ; Sun, Xi ; Gao, Minjie ; Gao, Lu ; Wu, Xiaosong ; Tao, Yi ; Zhu, Weiliang ; Shi, Jumei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c316t-c4798303d1445b3bb810131f0cddd668e1d6029e242e890ff9bc55c070dc72013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cell Line, Tumor</topic><topic>Dobutamine - therapeutic use</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Mitogen-Activated Protein Kinases - drug effects</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - pathology</topic><topic>丝裂原活化蛋白激酶</topic><topic>体外</topic><topic>信号通路</topic><topic>免疫球蛋白</topic><topic>多发性骨髓瘤</topic><topic>患者</topic><topic>抗肿瘤作用</topic><topic>沙利度胺</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xie, Bingqian</creatorcontrib><creatorcontrib>Xu, Zhijian</creatorcontrib><creatorcontrib>Yang, Guang</creatorcontrib><creatorcontrib>Chen, Gege</creatorcontrib><creatorcontrib>Li, Bo</creatorcontrib><creatorcontrib>Hu, Liangning</creatorcontrib><creatorcontrib>Xiao, Wenqin</creatorcontrib><creatorcontrib>Sun, Xi</creatorcontrib><creatorcontrib>Gao, Minjie</creatorcontrib><creatorcontrib>Gao, Lu</creatorcontrib><creatorcontrib>Wu, Xiaosong</creatorcontrib><creatorcontrib>Tao, Yi</creatorcontrib><creatorcontrib>Zhu, Weiliang</creatorcontrib><creatorcontrib>Shi, Jumei</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-自然科学</collection><collection>中文科技期刊数据库-自然科学-生物科学</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta biochimica et biophysica Sinica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xie, Bingqian</au><au>Xu, Zhijian</au><au>Yang, Guang</au><au>Chen, Gege</au><au>Li, Bo</au><au>Hu, Liangning</au><au>Xiao, Wenqin</au><au>Sun, Xi</au><au>Gao, Minjie</au><au>Gao, Lu</au><au>Wu, Xiaosong</au><au>Tao, Yi</au><au>Zhu, Weiliang</au><au>Shi, Jumei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antitumor effect of dobutamine on multiple myeloma via mitogen-activated protein kinase pathway in vitro</atitle><jtitle>Acta biochimica et biophysica Sinica</jtitle><addtitle>Acta Biochimica et Biophysica Sinica</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>48</volume><issue>12</issue><spage>1135</spage><epage>1137</epage><pages>1135-1137</pages><issn>1672-9145</issn><eissn>1745-7270</eissn><abstract>Multiple myeloma （MM） is one of the most malignant cancers and is characterized by infiltration of bone marrow by plasma cells, secretion of monoclonal immunoglobulins and osteolytic lesions, and its incidence is increasing in the middle-aged and elderly patients . As MM cells are heterogeneous and drug resistant, ini- tial MM usually progresses to the relapsed/refractory stage. Although existing therapies such as thalidomide, bortezomib, and lenalidomide can prolong the survival of MM patients, MM is still regarded as incurable. Therefore, it is necessary to establish new effective therapies to treat relapsed/refractory MM.</abstract><cop>China</cop><pmid>27797722</pmid><doi>10.1093/abbs/gmw110</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1672-9145 |
| ispartof | Acta biochimica et biophysica Sinica, 2016-12, Vol.48 (12), p.1135-1137 |
| issn | 1672-9145 1745-7270 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1834997706 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents - therapeutic use Cell Line, Tumor Dobutamine - therapeutic use Humans In Vitro Techniques Mitogen-Activated Protein Kinases - drug effects Multiple Myeloma - drug therapy Multiple Myeloma - pathology 丝裂原活化蛋白激酶 体外 信号通路 免疫球蛋白 多发性骨髓瘤 患者 抗肿瘤作用 沙利度胺 |
| title | Antitumor effect of dobutamine on multiple myeloma via mitogen-activated protein kinase pathway in vitro |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T21%3A50%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antitumor%20effect%20of%20dobutamine%20on%20multiple%20myeloma%20via%20mitogen-activated%20protein%20kinase%20pathway%20in%20vitro&rft.jtitle=Acta%20biochimica%20et%20biophysica%20Sinica&rft.au=Xie,%20Bingqian&rft.date=2016-12-01&rft.volume=48&rft.issue=12&rft.spage=1135&rft.epage=1137&rft.pages=1135-1137&rft.issn=1672-9145&rft.eissn=1745-7270&rft_id=info:doi/10.1093/abbs/gmw110&rft_dat=%3Cproquest_cross%3E1834997706%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1834997706&rft_id=info:pmid/27797722&rft_cqvip_id=671151492&rfr_iscdi=true |